Revvity (RVTY) to Release Quarterly Earnings on Monday

Revvity (NYSE:RVTY) will be announcing its earnings results before the market opens on Monday, April 29th. Analysts expect the company to announce earnings of $0.94 per share for the quarter. Revvity has set its FY 2024 guidance at 4.550-4.750 EPS and its FY24 guidance at $4.55-$4.75 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Revvity (NYSE:RVTY) last issued its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The business had revenue of $695.90 million for the quarter. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Revvity Trading Down 0.6 %

Shares of RVTY stock opened at $101.51 on Friday. The company’s fifty day simple moving average is $104.66 and its two-hundred day simple moving average is $101.40. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. Revvity has a 1 year low of $79.50 and a 1 year high of $132.54. The stock has a market capitalization of $12.54 billion, a price-to-earnings ratio of 18.46, a PEG ratio of 2.66 and a beta of 1.09.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. Revvity’s payout ratio is 5.09%.

Insider Buying and Selling

In related news, insider Prahlad R. Singh sold 21,217 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on RVTY shares. Raymond James boosted their target price on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus boosted their price target on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. KeyCorp boosted their price target on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Finally, Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and boosted their price target for the company from $88.00 to $125.00 in a research report on Thursday, January 4th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Revvity presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.91.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.